Ping An Biomedical Co., Ltd. (PASW) Stock Price & Analysis
Ping An Biomedical Co., Ltd. (PASW) — MoonshotScore 29/100 (Weak band), calculated Nov 18, 2026. Price $1.26 (-10.00%), as of the Nov 19, 2026 trading session; market cap $3.56M.
Educational signal · not a buy or sell recommendation · How to read this
Ping An Biomedical Co., Ltd. · PASW · NASDAQ
Ping An Biomedical Co., Ltd. is a supply chain management company in the apparel industry, offering one-stop solutions for yarn products, textiles, and finished garments.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Ping An Biomedical Co. (PASW)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Bottom-tier quality, a strained balance sheet and stalling growth, and it’s expensive on top — broad distress, a capital-preservation call, not a value entry. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Strained; Valuation: Rich; Growth Durability: Shrinking; Momentum: Falling.
Earnings yield is the main valuation drag relative to sector peers.
- quarterly revenue CN¥5M (Q2 FY2026, quarter ended Mar 31, 2026)
- Altman Z 0.89 · Piotroski F 2
- ROE -6.1% · ROA -3.8% · current ratio 2.54 · earnings yield -29.3% · free-cash-flow yield -19.2%
Holding back: weak fundamentals, balance-sheet strain, a rich price, soft growth, weak price trend
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 28 | Weak | |
| 28 | Weak | |
| 28 | Weak | |
| 28 | Weak | |
| 29 | Weak | |
| 29 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $1.26 | |
| Change on the day | -10.00% | |
| 52-week range | $1.07 – $28.56 | |
| Market capitalisation | $3.56M | — |
| Shares traded on the day | 8.1K |
Price & events
Other perspectives
Council score for Ping An Biomedical Co. (PASW): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 16, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 5, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 5, 2026, the Munger lens read the price at that time as overvalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Ping An Biomedical Co. (PASW), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Ping An Biomedical Co., Ltd. (PASW) is listed on NASDAQ. It employs 7 people and is led by Pijun Liu. In Q2 FY2026 it reported revenue of CN¥5M and net income of CN¥2M. The market values it at $3.56M.
What do the latest results show for Ping An Biomedical Co. (PASW)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of CN¥5M.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | CN¥5M | CN¥2M | CN¥1.91 (diluted) |
| Q1 FY2026 | CN¥5M | CN¥2M | CN¥1.91 (diluted) |
| Q4 FY2025 | CN¥8M | -CN¥4M | -CN¥9.20 (diluted) |
| Q3 FY2025 | CN¥8M | -CN¥4M | -CN¥9.20 (diluted) |
What are the financial strengths and risks for Ping An Biomedical Co. (PASW)?
Short answer · as of
What is holding it back is weak fundamentals, balance-sheet strain, a rich price, soft growth, weak price trend. The distress and quality screens read Altman Z 0.89 · Piotroski F 2. Trailing ratios: ROE -6.1% · ROA -3.8% · current ratio 2.54 · earnings yield -29.3% · free-cash-flow yield -19.2%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of 0.89 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-6.1%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
How does Ping An Biomedical Co. compare with its peers?
Short answer
Ping An Biomedical Co.'s score ranks 1st of 2 in the bounded comparison shown, against 1 same-model peer. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| Ping An Biomedical Co. (PASW) — this page | $1.26 | $3.56M | 29 |
| $7.38 Nov 19, 2026 | $13.4M | 27 5-pillar Nov 18, 2026 | |
| $2.80 Nov 19, 2026 | $14.6M | — Model unavailable | |
| $0.42 Aug 21, 2026 | $14.3M | — Model unavailable |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held PASW in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported PASW in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Ping An Biomedical Co. (PASW)?
What Investors Ask About Ping An Biomedical Co. (PASW)
These answers are editorial: 1 of these 9 answers is drawn from the PASW research dossier (written Mar 17, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for PASW?
PASW carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is PASW a good stock to buy?
Stock Expert AI does not rate PASW buy, sell or hold. Ping An Biomedical Co., Ltd. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the PASW stock price today?
The last price recorded for Ping An Biomedical Co., Ltd. (PASW), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What does Ping An Biomedical Co., Ltd. do?
Ping An Biomedical Co., Ltd. operates as a supply chain management provider within the apparel industry. The company offers a comprehensive suite of services, acting as a one-stop solution for clients seeking yarn products, textiles, and finished garments.
What are the key factors to evaluate for PASW?
Ping An Biomedical Co., Ltd. (PASW) holds a MoonshotScore in the low range. Ping An Biomedical Co., Ltd. operates in the apparel supply chain management sector, providing one-stop solutions for yarn products, textiles, and finished garments. Not financial advice.
How frequently does PASW data refresh on this page?
PASW's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven PASW's recent stock price performance?
Ping An Biomedical Co., Ltd. (PASW) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: One-stop solution for apparel supply chain management. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PASW overvalued or undervalued right now?
Ping An Biomedical Co., Ltd. (PASW) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of PASW?
Fractional-share availability for Ping An Biomedical Co., Ltd. (PASW) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 15 figures on this page — 7 from Financial Modeling Prep (FMP), 6 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com